Transcatheter aortic valve implantation and surgical aortic valve replacement among hospitalized patients with and without type 2 diabetes mellitus in Spain (2014-2015)

• Published in: Cardiovascular diabetology 2017-11, Vol.16 (1), p.144-144, Article 144
• Main Authors: Mendez-Bailon, Manuel, Lorenzo-Villalba, Noel, Muñoz-Rivas, Nuria, de Miguel-Yanes, Jose Maria, De Miguel-Diez, Javier, Comín-Colet, Josep, Hernandez-Barrera, Valentin, Jimenez-Garcia, Rodrigo, Lopez-de-Andres, Ana
• Format: Article
• Language: English
• Subjects: Aortic stenosis; Aortic valve; Cardiovascular diseases; Clinical trials; Complications; Data processing; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Heart; Hospital; Hospitals; Implantation; Mortality; Obesity; Original Investigation; Patients; Prognosis; Risk factors; Statistical analysis; Stenosis; Studies; Surgical aortic valve replacement; Transcatheter aortic valve implantation; Type 2 diabetes; Variables
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-017-0631-6

Type 2 diabetes mellitus (T2DM) is strongly related to the in-hospital and short-term prognosis in patients with cardiovascular diseases needing surgical or invasive interventions. How T2DM might influence the treatment of aortic stenosis (AS) has not been completely elucidated for surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). The aims of this study were: (1) to describe the use of aortic valve replacement procedures (TAVI and SAVR) among hospitalized patients with and without T2DM; and (2) to identify factors associated with in hospital mortality (IHM) among patients undergoing these procedures. We analyzed data from the Spanish National Hospital Discharge Database between January 1, 2014 and December 31, 2015 for patients aged ≥ 40 years. We selected patients whose medical procedures included TAVI (ICD-9-CM codes 35.05, 35.06) and SAVR (ICD-9-CM codes 35.21, 35.22). We stratified each cohort by diabetes status: T2DM (ICD-9-CM codes 250.x0, 250.x2) and no diabetes. We retrieved data about specific comorbidities, risk factors, procedures, and specific in-hospital postoperative complications. Hospital outcome variables included IHM, and length of hospital stay (LOHS). We identified a total of 2141 and 16,013 patients who underwent TAVI (n = 715; 33.39% with T2DM) and SAVR (n = 4057; 25.33% with T2DM). In patients who underwent TAVI we found no differences in IHM (3.64% in T2DM vs. 5.12% in non-T2DM, p = 0.603). In the cohort of SAVR, mean LOHS was significantly lower in patients with T2DM than in non-diabetic patients (13.77 vs. 17.27 days). IHM was lower in patients with T2DM (4.36% vs. 6.31%, p